10月15日，福泰制药盘中上涨3.13%，报500.5599美元/股，成交额5.74亿美元。
此次异动的消息面，仍与公司此前披露的肾病在研药物Inaxaplin积极临床进展有关。
公司此前公布，Inaxaplin在APOL1介导肾病2b期研究中，于第13周实现42.7%的蛋白尿降幅，合并2型糖尿病患者降幅为17.3%，且未报告药物相关严重不良事件；同时更大规模的2/3期试验已完成入组。结合近期机构恢复覆盖并给出积极评级，市场对其中长期管线价值预期仍偏正面。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.